STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of stockholders' equity, outstanding warrants


		Warrants
		outstanding as of	Exercise
		December 31, 2025	price $	Expiration date
Consultants		14,250	32.00	December 31, 2026
Consultants		2,000	69.20	December 31, 2026
Consultants		6,500	32.00	December 31, 2026
Consultants		2,813	16.00	December 31, 2026
Consultants		25,000	32.00	December 31, 2026
Consultants		1,500	40.00	December 31, 2026
Consultants		15,000	28.60	December 31, 2026
Consultants		5,000	32.00	December 31, 2026
Consultants		5,000	18.59	August 24, 2027
Consultants		43,375	14.00	December 31, 2027
Consultants		52,500	12.80	February 10, 2028
Lender of loan facility		14,623	14.42	May 1, 2028
Lender of loan facility		14,623	14.42	May 1, 2028
Consultants		22,500	14.20	June 1, 2028
Agent warrants C Feb. 21, 2024		53,443	40.40	February 21, 2029
Agent warrants C-2 Feb. 21, 2024		3,543	42.80	February 21, 2029
Consultants		688	14.00	August 1, 2029
Consultants		25,000	18.59	August 25, 2029
Consultants		5,328	18.95	November 4, 2029
Lender of loan facility		268,579	15.35	April 30, 2032
Consultants		35,898	51.00	February 15, 2034
		617,163

Schedule of stock option activity

Transactions related to the grant of options to employees, directors and non-employees under the above plans and non-plan options during the year ended December 31, 2025 were as follows:


						Weighted
				Weighted		average
				average		remaining	Aggregate
				exercise		contractual	Intrinsic
		Number of		price		life	value
		options**		$		Years	$
Options outstanding at beginning of period		511,138		55.61		8.55	9
Options granted		86,224		15.38		—	—
Options exercised		—		—		—	—
Options expired		(127,386)		81.94		—	—
Options forfeited		(133,208)		28.13		—	—

Options outstanding at end of period		336,768		46.21		8.16	4

Options vested and expected to vest at end of period		255,827		44.01		8.14	3

Exercisable at end of period		142,433		77.05		7.24	3

(**) See note 1e regarding reverse share split.

Schedule of restricted stock option activity

Transactions related to the movement of restricted shares of Common Stock to employees, directors, and non-employees under the above plans during the year ended December 31, 2025 were as follows:


								Number of
								Restricted shares**

Restricted shares outstanding at beginning of year								270,420
Restricted shares granted								364,950
Restricted shares forfeited								(21,905)

Restricted shares outstanding at end of period (***)								613,465

Schedule of assumptions used to estimate the fair values of the options granted to employees, directors and non-employees


	Year ended
	December 31,
	2025		2024
Volatility	96.72-102.47	%	94.75-97.97	%
Risk-free interest rate	3.82-4.23	%	3.67-4.72	%
Dividend yield	0	%	0	%
Expected life (years)	5.00-5.87		5.00-5.87

Schedule of compensation cost


	Year ended
	December 31,
	2025		2024
Cost of revenues	$	25	$	13
Research and development		1,626		3,296
Sales and marketing		2,253		4,890
General and administrative		5,461		7,597

Total stock-based compensation expenses	$	9,365	$	15,796